Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.

about

Tackling non-muscle invasive bladder cancer in the clinic.Alternative therapies in patients with non-muscle invasive bladder cancer.Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

P2860

Q39209020-7C1CC1E1-0299-433E-8997-FDA71C3420A4 Q47114392-28236D08-9487-44EA-A059-D2180AECE8B1 Q47406496-024B76C2-7AF3-4FE5-9F73-B67EEFB11490

P2860

Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.

Item

http://www.wikidata.org/entity/Q38823147

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Vesigenurtacel-L (HS-410) in t ...... uscle invasive bladder cancer.

@en

type

Item

label

Vesigenurtacel-L (HS-410) in t ...... uscle invasive bladder cancer.

@en

prefLabel

Vesigenurtacel-L (HS-410) in t ...... uscle invasive bladder cancer.

@en

P1476

Vesigenurtacel-L (HS-410) in t ...... uscle invasive bladder cancer.

@en

P2093

Aryeh Keehn

http://www.w3.org/2001/XMLSchema#string

Benjamin Gartrell

http://www.w3.org/2001/XMLSchema#string

Mark P Schoenberg

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu

Discovery of the heat shock response

Molecular and cellular insights into T cell exhaustion

Allogeneic tumor cell vaccines: the promise and limitations in clinical trials

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway.

The role of heat shock proteins and their receptors in the activation of the immune system.

Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.

P304

2673-2682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0284

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27609194

http://www.w3.org/2001/XMLSchema#string

Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.

about

P2860

P2860

Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698